Hi all, my mom had RUL lobectomy in September, 2017 and finally finished adjuvant chemo last week. At the last meeting with her oncologist, he recommended her to go on a phase Ⅲ trial for adjuvant Pembrolizumab after resection with standard adjuvant chemo (vs. Placebo). We're still considering whether she'll be on it or not.
Here is brief information about my mom.
- fully resected stageⅡb NSCLC (invasive ademocarcinoma, grade 3)
- completed 4 cycles of adjuvant chemo (NP)
- EGFR mutation - exon 21(L861Q)
- PD-L1 expression 30%
As you can see, she is both EGFR and PD-L1 positive.
It could mean we have more options if the cancer comes back later.
Using Pembrolizumab in advance may prevent recurrence but if it doesn’t work well, it might limit our treatment option.
Is there prior or updated study results about adjuvant pembrolizumab?
If there is, it will be very helpful for me to make a decision.
Thank you all in advance.